DOW JONES26,957.59-123.77 -0.46%
S&P 5003,116.39-11.82 -0.38%
NASDAQ8,980.78+15.16 0.17%

Roth Capital Assumes Cellectar Biosciences at Buy, Announces $10 Price Target

Roth Capital analyst Jonathan Aschoff assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and a $10 price target.

Benzinga · 01/21/2020 14:05

Roth Capital analyst Jonathan Aschoff assumes Cellectar Biosciences (NASDAQ:CLRB) with a Buy rating and a $10 price target.